Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aclidinium Bromide Drug Utilisation Post-Authorisation Safety Studies (DUS): Common Protocol for Aclidinium (DUS1) and Aclidinium/Formoterol Fixed-Dose Combination (DUS2)

NCT03333018 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03333018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03333018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aclidinium Bromide Drug Utilisation Post-Authorisation Safety Studies (DUS): Common Protocol for Aclidinium (DUS1) and Aclidinium/Formoterol Fixed-Dose Combination (DUS2)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
July 6, 2015
Completion date
February 28, 2017
Enrollment
22,155 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive